

## Product Update:

### ipilimumab 5mg/mL concentrate for solution for infusion (Yervoy®) SMC2094 Bristol-Myers Squibb

7 September 2018

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarized as follows:

**ADVICE:** following an abbreviated submission

**ipilimumab (Yervoy®)** is accepted for use within NHSScotland.

**Indication under review:** as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age and older.

SMC has previously accepted ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in previously untreated adult patients ([No. 997/14](#)) and in adults who have received prior therapy ([No. 779/12](#)).

Ipilimumab was accepted for use in previously untreated patients ([No. 997/14](#)) following a submission under the end of life and orphan process.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ipilimumab. This SMC advice is contingent upon the continuing availability of the patient access scheme or a list price that is equivalent or lower.

Patient access schemes: A patient access scheme is a scheme proposed by a pharmaceutical company in order to improve the cost-effectiveness of a medicine and enable patients to receive access to cost-effective innovative medicines. A Patient Access Scheme Assessment Group (PASAG), established under the auspices of NHS National Services Scotland reviews and advises NHSScotland on the feasibility of proposed schemes for implementation. The PASAG operates separately from SMC in order to maintain the integrity and independence of the assessment process of the SMC. When SMC accepts a medicine for use in NHSScotland on the basis of a patient access scheme that has been considered feasible by PASAG, a set of guidance notes on the operation of the scheme will be circulated to Area Drug and Therapeutics Committees and NHS Boards prior to publication of SMC advice.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of*

*Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 17 August 2018.*

**Chairman  
Scottish Medicines Consortium**